Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Molecular Diagnostics, UCLA Plan Melanoma Test in 06

NEW YORK, Dec. 7 (GenomeWeb News) - CombiMatrix Molecular Diagnostics and researchers at the University of California, Los Angeles plan to use CombiMatrix's microarray technology to create a diagnostic for malignant melanoma.


The UCLA group, led by Scott Binder at the Department of Pathology and Laboratory Medicine at the Geffen School of Medicine, will work with CMD using routinely prepared formalin-fixed paraffin-embedded material. Binder's team will also provide clinically validated patient samples for the validation phase of the project.


The test is aimed at helping pathologists discriminate between atypical pigmented moles and malignant melanoma, CMD and UCLA said.


Matt Watson, CEO of CMD, said that if his firm can "gain CLIA certification in early 2006, and [its] development efforts proceed as planned, [CMD hopes] to have this test available to physicians and patients by the middle of 2006."


Separately, CMD this week announced plans to offer a DNA-based microarray service to identify types of influenza. The company is a wholly-owned subsidiary of CombiMatrix, which formed the company last May.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.